PMID- 32753963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the 
      Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective 
      Study.
PG  - 5461-5468
LID - 10.2147/CMAR.S255960 [doi]
AB  - PURPOSE: To evaluate the efficacy and safety of drug-eluting beads transarterial 
      chemoembolization (DEB-TACE) and conventional TACE (C-TACE) in treating 
      hypovascular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The medical 
      records based on HCC patients who underwent TACE from January 2016 to June 2019 
      were reviewed in the study. The diagnosis of hypovascular HCC was conducted by 
      two senior radiologists according to imaging. We evaluated the adverse events 
      (AEs), objective response rate (ORR), disease control rate (DCR), 
      progression-free survival (PFS) and overall survival (OS) in the study. RESULTS: 
      A total of 98 patients with hypovascular HCC were included in the study. 46 
      patients underwent DEB-TACE treatment, and 52 patients underwent C-TACE 
      treatment. The PFS of DEB-TACE group and C-TACE group was 12.0 months and 7.0 
      months (P < 0.001), and OS was 21.0 months and 14.0 months (P = 0.035), 
      respectively. In addition, DEB-TACE group had better ORR (76.1% vs 40.4%, P < 
      0.001) and DCR (91.3% vs 75.0%, P = 0.033) compared to C-TACE group. The 
      occurrence rate of AEs showed no difference between the two groups (67.3% vs 
      57.7%, P = 0.323). Furthermore, we found that DEB-TACE can be identified as a 
      positive independent prognostic factor for improved PFS and OS. CONCLUSION: 
      DEB-TACE, as an effective treatment, can yield better objective response rate, 
      similar safety profile and improved survival for hypovascular HCC patients 
      compared to C-TACE.
CI  - (c) 2020 Shi et al.
FAU - Shi, Qin
AU  - Shi Q
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
FAU - Chen, Dandan
AU  - Chen D
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
AD  - Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
FAU - Zhou, Chen
AU  - Zhou C
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
FAU - Liu, Jiacheng
AU  - Liu J
AUID- ORCID: 0000-0002-7786-9957
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
FAU - Huang, Songjiang
AU  - Huang S
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
FAU - Yang, Chongtu
AU  - Yang C
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
FAU - Xiong, Bin
AU  - Xiong B
AUID- ORCID: 0000-0002-7795-7041
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, People's Republic of China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7351634
OTO - NOTNLM
OT  - drug-eluting beads
OT  - hypovascular hepatocellular carcinoma
OT  - lipiodol
OT  - survival
OT  - transarterial chemoembolization
COIS- All authors declare that they have no conflicts of interest in this work.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
PMCR- 2020/07/06
CRDT- 2020/08/06 06:00
PHST- 2020/03/28 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
PHST- 2020/07/06 00:00 [pmc-release]
AID - 255960 [pii]
AID - 10.2147/CMAR.S255960 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Jul 6;12:5461-5468. doi: 10.2147/CMAR.S255960. eCollection 
      2020.